Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of apatinib for liver cancer in Shandong
ChiCTR1900021822Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of latanoprost and Rivoceranib in hepatocellular carcinoma (HCC) and liver cancer, sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: overall survival, progression-free survival and 3 more. Started Feb 2019; status: recruiting.
02
Drugs
latanoprostRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ChiCTR1900021822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021822.